Past Global Symposiums
31st January 2024
| TIME | PROGRAMME |
|---|---|
| 09:00 – 09:05 | WELCOME |
| 09:05 – 10:30 |  WAO SESSION – IMMUNOTHERAPY Chairs:
|
| 09.05 – 09.20 | Personalized medicine in immunotherapy
AIT is a paradigmatic example of Disease Modyfing Treatment and of Personalized Medicine. The Molecular Allergy Diagnosis (or Component Diagnosis or PAMD@) is a clear added value in defining the true sensitization in allergic patients and the possibility of shared decision with patients about SCIT.
Giorgio Walter Canonica, Humanitas Research Hospital, Italy |
| 09.20 – 09.35 | Immunotherapy and component testing: potential role in the future
The first premise for the prescription of immunotherapy based on PAMD@ is the assessment of IgE positivity to genuine versus cross-reactive allergens. Allergen immunotherapy should be prescribed to patients with demonstrated IgE-mediated sensitivity to relevant allergens that induce clinical manifestations.
Ignacio J. Ansotegui, Hospital Quironsalud Bizkaia, Spain |
| 09.35 – 09.50 | Oral Immunotherapy: A shared-decision discussion
Two clinicians will discuss 5 key questions most allergists and patients are asking about OIT. Practical advice on how to have an informative and effective shared-decision making conversation with a patient who is considering oral immunotherapy.
Dana Wallace, Nova Southeastern University College of Allopathic Medicine Fort Lauderdale, USA |
| 09.50 – 10.05 | Using immunotherapy to prevent the atopic march. Mário Morais-Almeida, CUF – Hospitais e Clínicas, Portugal |
| 10.05 – 10.30 | Panel Q&A |
| 10:30 – 10:45 | BREAK |
10:45 – 12:10 |
 EAACI UPDATE Chairs:
|
| 10.45 – 11.00 | New nomenclature on allergic diseases. From Bench to bedside
The cultural change brought by the new nomenclature will lead to novel concepts of diagnostic tools, improving therapies, and disease management and will guide future research into more innovative strategies for patient care.
Marek Jutel, Wroclaw Medical University, Poland |
| 11.00 – 11.15 | EAACI Guidelines on the diagnosis and management of IgE-mediated food allergy
This talk will provide clear and practical recommendations to be applied in clinical practice in order to improve the accuracy of food allergy diagnosis around the world.
Alexandra F. Santos, King’s College London, UK |
| 11.15 – 11.30 | Allergy to stings and bites from non-Hymenoptera insects: available diagnostics and treatment
Allergy to rare or locally important arthropods is not well known. The key is to be aware of rare arthropods and learn how to diagnose and treat allergy.
Gunter Sturm, Medical University of Graz, Austria |
| 11.30 – 11.45 | Severe asthma in real life. The EARL initiative
The EAACI EARL program is working on integrating Real-World evidence and EBM in health guidelines, since a defined method about how to integrate RWE in guidelines is still missing. Delegates will learn the value of RWE and the proposal to create guidelines on the correct methodology to handle data coming from randomized, non-randomized studies and from registries.
Stefano Del Giacco, University of Cagliari, Italy |
| 11.45 – 12.10 | Panel Q&A |
| 12.10 – 12.40 | BREAK |
| 12.40 – 13.50 | Presidents’ Forum The presidents of the partner Societies will revisit the allergy state-of-the-art Chair:
Speakers: |
| 13.50 – 14.10 | BREAK |
14:10 – 15.35 |
 BSACI SESSION – CHALLENGING INTERACTIVE CASES Chairs:
|
| 14.10 – 14.25 | Food allergy cases
Composite dishes often make it difficult to track down the allergen responsible for food allergic reactions. It is key to take a detailed history of exactly what was in the dish that provoked symptoms and undertake a food challenge if the history does not match the test results.
Isabel Skypala, Guys and St Thomas NHS Foundation Trust & Imperial College, UK |
| 14.25 – 14.40 | Perioperative allergy cases
Perioperative allergy is a rare but devasting event which can be uniquely challenging to recognise, investigate and diagnose. This session will cover some of the complexities and pitfalls in the end-to-end journey from initial event to eventual diagnosis.
Louise Savic, Leeds Teaching Hospitals NHS Trust, UK |
| 14.40 – 14.55 | Gastro Allergy cases
Multi-system allergic disease is increasing globally. Although many will be aware about the increases in allergy respiratory and dermatological presentations, gastro-intestinal conditions are also seeing a significant rise in prevalence.
|
| 14.55 – 15.10 | Immunodeficiency cases
This talk highlights presentation of interesting immunodeficiency cases, how they are diagnosed and how to manage these patients.
Ariharan Anantharachagan, Lancashire Teaching Hospitals NHS Foundation Trust, UK |
| 15.10 – 15.35 | Panel Q&A |
| 15:35 – 15:50 | BREAK |
| 15:50 – 16:50 | COMPANY SYMPOSIUM
DBV Technologies
Epicutaneous immunotherapy for peanut allergy: from science to clinical practice
|
16.50 – 18:15 |
 AAAAI UPDATE Chairs:
|
| 16.50 – 17.05 | The ACAAI/AAAAI Atopic Dermatitis guidelines
The Atopic Dermatitis Guidelines: 2023 AAAAI/ACAAI Joint Task Force (JTF) on Practice Parameters GRADE- and Institute of Medicine-based recommendations will assist clinicians in caring for their patients with atopic dermatitis.
Lynda Schneider, Harvard Medical School & Boston Children’s Hospital, USA |
| 17.05 – 17.20 | GRADE guidelines for chronic rhinosinusitis with nasal polyps
An update of the JTF chronic rhinosinusitis with NP guidelines which is a very common clinical presentation seen by Allergists and Immunologists. This is a GRADE document so the certainty of medical evidence supporting recommendations is provided. This talk could reaffirm or change the way clinicians are currently managing their patients with CRSwNP.
Jonathan Bernstein, University of Cincinnati College of Medicine, Bernstein Allergy group and Bernstein Clinical Research Center, USA |
| 17.20 – 17.35 | Asthma: What’s new in EPR4 and GINA.
Evidence based strategies for the management of asthma in all age groups are available to improve the care of children with asthma around the world.
Leonard Bacharier, Vanderbilt University Medical Center, USA |
| 17.35 – 17.50 | Drug Allergy: A Practise parameter update
The US Joint Task Force recently completed an update to the drug allergy practice parameters. This update was a data-derived and expert consensus document covering key areas of drug allergy. This session will aim to improve the global understanding of the US drug allergy practice parameter approaches to antibiotic allergy assessment and de-labeling.
Kimberly Blumenthal, Mass General Brigham, USA |
| 17.50 – 18.15 | Panel Q&A |
| 18:15 – 18:20 | CLOSING AND PRESIDENTS’ REMARKS |
10th February 2023
| TIME | PROGRAMME |
|---|---|
| 08:00 – 08:15 | WELCOME |
| 08:15 – 09:40 |
WAO SESSION – DRUG ALLERGY |
| Drug Desensitization Ricardo Madrigal-Burgaleta, St Bartholomew’s Hospital, Barts Health NHS Trust, UK MRGPRX2 – future therapeutics for drug allergy Pedro Giavina-Bianchi, Clinical Immunology and Allergy Division of University of São Paulo, Brazil Computer aided early diagnosis of SJS/TEN Riichiro Abe, Niigata Graduate School of Medical and Dental Sciences, Japan Chaired by: WAO representative Pascal Demoly, University hospital of Montpellier, France and BSACI representative Rubaiyat Haque, Guy’s and St Thomas’ NHS Foundation Trust, UK Panel Q+A |
|
| 09:40 – 10:40 | COMPANY SYMPOSIUM |
| 10:40 – 10:50 | BREAK |
| 10:50 – 12:15 |
EAACI SESSION – ENVIRONMENTAL IMPACT ON ALLERGY |
| Microbiome for allergy prevention Erika von Mutius, LMU, Germany Climate change and the changing allergen landscape Isabella Pali-Schöll, University of Veterinary Medicine & Medical University of Vienna, Austria Infection and immune interactions in the airways Jürgen Schwarze, University of Edinburgh, UK Panel Q+A Chaired by: EAACI representative Mohamed Shamji, Imperial College London, UK and BSACI representative Glenis Scadding, Royal National ENT Hospital and University College London, UK |
|
| 12:15 – 12:30 | BREAK |
| 12:30 – 13:00 | Keynote Lecture CALL to ACTION: Environmental causes of allergic disease and effective interventions – What should we do as an allergy community? Stephen Holgate, University of Southampton, UK |
| 13:00 – 14:15 | BREAK |
| 14:15 – 15:40 |
BSACI SESSION – CHALLENGES IN ALLERGY |
| FPIES and EOE in adults Isabel Skypala, Royal Brompton & Harefield Hospitals – part of Guys & St Thomas NHS Foundation Trust, UK Difficult conversations with adolescents and young adults Claudia Gore, Imperial College Healthcare NHS Trust, UK The future of allergy diagnostics Alexandra Santos, King’s College London and Evelina London Children’s Hospital, UK Panel Q+A Chaired by: BSACI representatives Susana Marinho, University of Manchester, UK and Marta Vazquez-Ortiz, Imperial College London, UK |
|
| 15:40 – 16:40 | COMPANY SYMPOSIUM |
| 16:40 – 16:50 | BREAK |
| 16:50 – 18:15 |
AAAAI SESSION – IMMUNOTHERAPY |
| Avoidance to remission to cure – how far does immunotherapy take us? Wayne Shreffler, Massachusetts General Hospital / Harvard Medical School, USA Future Adjuvants in Immunotherapy J. Andrew Bird, University of Texas Southwestern Medical Center, USA Conversations with patients about food oral immunotherapy R. Sharon Chinthrajah & Sayantani Sindher, Stanford University, USA Panel Q+A Chaired by: AAAAI representative Brian P. Vickery, Emory University and Children’s Healthcare of Atlanta, USA and BSACI representative Stephen Durham, Imperial College London and Royal Brompton Hospital London, UK |
|
| 18:15 – 18:30 | CLOSING AND PRESIDENTS’ REMARKS |